COMPANY PROFILE

DIADEM

Explore full profile

Improves clinicians/patient understanding about risk of Dementia/Alzheimer’s to enable earlier decisions and outcome

London, United KingdomFounded 2012Biotech & Life Sciences

Valuation $25–50M Last recorded · 2022

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About DIADEM

Diadem is a diagnostic company focused on developing early peripheral markers of disease into advanced diagnostic technology. The company specializes in creating a blood-based test that targets a specific conformation of the p53 protein, which has shown high sensitivity and specificity for Alzheimer's Disease (AD) in pilot clinical studies. This test, known as Predict, can identify the risk of cognitive decline in both symptomatic and asymptomatic elderly patients, enabling early intervention and more effective drug development. Diadem's core market includes healthcare providers, pharmaceutical companies, and clinical research organizations. The business model revolves around providing diagnostic tests that are fast, cost-effective, and non-invasive, thereby generating revenue through test sales and partnerships with pharmaceutical companies for clinical trials. The company's innovative approach aims to improve patient outcomes and streamline the drug development process for AD.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2012
Headquarters: London, United Kingdom
Employees: 10
Open positions: None listed
Dealroom signal: 82.1/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Hard Tech, proteomics, DT and LS, uk is8 life sciences, science-based
Business model: Marketplace & ecommerce
Client focus: b2b, b2c
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Aug 2026	$0	—	Seed Healthcare	↗
GRANTOther financing	Sep 2022	$2.5M	—	National Institute on Aging	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

DIADEM website traffic

Latest recorded traffic for DIADEM is 2.5K monthly website visits, up 0% over the last three months. DIADEM's team grew 42.9% over the past year.

Latest monthly visits2.5K 3-month web change0% 1-year team growth+42.9%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
WAWaveBreakSmall-molecule therapeutics for neurodegenerative diseases	Cambridge, United Kingdom	Operational	7	$40M	$119M
ABAbzenaIntegrated CDMO services for complex biologics and bioconjugates	Babraham, United Kingdom	Acquired
TPTauRx PharmaceuticalsDeveloping tau aggregation inhibitors for neurodegenerative diseases	Aberdeen, United Kingdom	Operational
ATAmphista TherapeuticsNext-generation therapeutics for targeted protein degradation	Great Abington, United Kingdom	Operational
IKIkarovecBi-functional gene therapies for chronic eye diseases	Norwich, United Kingdom	Operational
KIKinomicaPhosphoproteomic diagnostic platform for precision oncology therapy selection	Macclesfield, United Kingdom	Operational
ETEvox TherapeuticsExosome-based gene editing therapies for neurological diseases	Oxford, United Kingdom	Operational
SPSpyBiotechNovel vaccine platform using protein superglue technology	Oxford, United Kingdom	Operational